若生智能
Drug Database
LA

lansoprazole + amoxicillin + clarithromycin (Lansap)

✓ Approved

Takeda · ATP4A · 小分子

什么是 lansoprazole + amoxicillin + clarithromycin？

lansoprazole + amoxicillin + clarithromycin 是一种小分子，由Takeda研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Lansap
公司Takeda
药物类别小分子
分子靶点ATP4A
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Takeda

作用机制

分子靶点

lansoprazole + amoxicillin + clarithromycin 作用于 1 个分子靶点：

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lansoprazole + amoxicillin + clarithromycin 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastric ulcer✓ Approved
Infections and infestationsHelicobacter infection✓ Approved

相关研究文献

PubMedInfectious diseases now2026-06-13

Impact of discontinuing antibiotic susceptibility testing for Enterococcus faecalis-positive urine cultures on antibiotic prescriptions.

Baronnet Guillaume G, Jeanbert Elodie E, Emond Emeric E, Cailloux Philippe P et al.

This single-center, observational, retrospective, before-after comparative study conducted in a tertiary care public hospital assessed the impact of discontinuing routine antibiotic susceptibility testing for Enterococcus faecalis in urine cultures on antibiotic prescribing patterns. Secondary objectives were to evaluate prescriber acceptability and the impact of the intervention by patient sex and on targeted antibiotic therapies. A total of 229 consecutive monomicrobial E. faecalis-positive urine cultures from hospitalized adults were included. Two study periods were compared according to the intervention's implementation. In the pre-intervention period (December 2018-December 2019), antibiotic susceptibility testing was performed and fully reported, while in the post-intervention period (December 2019-December 2020), this was replaced by the following standardized sentence: "Species (usually) sensitive to amoxicillin; selective reporting of antibiotic susceptibility testing may be carried out upon request if there is a contraindication to the use of amoxicillin." Overall, 120 urine cultures were analyzed during the pre-intervention period and 109 during the post-intervention period. Penicillin prescriptions increased in the overall cohort (28/67 vs 36/55; p = 0.011) and among male patients (21/54 vs 24/33; p = 0.004). Non-significant decreases were observed in overall fluoroquinolone use (12/67 vs 3/55; p = 0.051) and targeted antibiotic therapies (9/39 vs 3/43, p = 0.059). Acceptability rate was high (97%). Discontinuation of routine antibiotic susceptibility testing reporting for E. faecalis-positive urine cultures was associated with a shift in antibiotic prescribing patterns, with increased penicillin use and a possible reduction in fluoroquinolone prescriptions.

PMID 42285230
阅读全文 →
PubMedBMJ case reports2026-06-13

Growth of Klebsiella pneumoniae from a recurrent non-lactational breast abscess.

Wiltshire Samuel S, Shrestha Anne A, Timma Subramanian Kumaresh K, Boland Gary G

Breast abscesses are localised infections that can be lactational or non-lactational. Non-lactational abscesses are more often associated with less common bacteria. We describe a case of Klebsiella pneumoniae as the causative bacteria of a non-lactational breast abscess. Resistance to amoxicillin was noted, and recurrence occurred despite multiple treatments with appropriate antibiotics. Definitive management required incision and drainage of the abscess. Our literature review shows 22 total cases of K. pneumoniae being isolated from breast abscesses, with only 9.1% of cases confirming full susceptibility to all tested antibiotics. Resistance to at least one antibiotic was seen in 45.5% of cases. The literature shows that rates of antibiotic resistance in K. pneumoniae are rising, and therefore, monitoring of antibiotic resistance in these patients may be indicated. Culture and sensitivity should be encouraged as this may guide management options for recurrent breast abscesses.

PMID 42285590
阅读全文 →
PubMedBioinformation2026-06-12

A prospective randomized study comparing amoxycillin/clavulanate (augmentin) with cefuroxime-metronidazole as prophylaxis in gynaecological surgery.

Soni Shambhavi S, Rathore Pradeep P, Tiwari Ashis A

Effective antibiotic prophylaxis is essential for preventing post-operative infections following gynecological surgery. This prospective randomized study conducted in a tertiary care hospital compared the efficacy of amoxicillin-clavulanate and cefuroxime-metronidazole as preoperative antibiotic regimens. Hence, two hundred women undergoing elective gynecological procedures were evenly divided into two groups: Group A received 1.2 g amoxicillin-clavulanate intravenously, while Group B received 1.5 g cefuroxime plus 500 mg metronidazole before surgical incision. Post-operative outcomes such as surgical site infection, febrile morbidity, urinary tract infections and duration of hospital stay were recorded and analyzed using SPSS, with significance set at p < 0.05. Thus, we show that both antibiotic combinations were equally effective in reducing post-operative infection rates and were well tolerated, supporting their safe use in gynecological surgery and the choice between regimens may depend on factors including hospital antibiotic policy, cost and local microbial resistance patterns.

PMID 42282362
阅读全文 →
PubMedHelicobacter2026-06-12

Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial.

Zhu Yu-Cheng YC, Li Keng K, Sun Anjiang A, Lin Sihui S et al.

Resistance to antibiotics has resulted in the effectiveness of conventional eradication therapies for Helicobacter pylori being reduced, creating a need for regimens that are effective, safe, and simple. In this study, we evaluated the eradication efficacy, adverse events, and medication adherence of four different tegoprazan-based regimens administered as first-line therapy for H. pylori infection. We also explored the clinical value of adding bismuth to a triple therapy regimen. In this prospective, randomized controlled trial, 640 treatment-naive patients with confirmed H. pylori infection were randomly assigned to one of the four groups undergoing 14-day treatment regimens of tegoprazan-amoxicillin (TA), tegoprazan-tetracycline (TT), tegoprazan-amoxicillin-tetracycline (TAT), or tegoprazan-amoxicillin-tetracycline-bismuth (TATB), with 160 patients in each group. The outcomes were the eradication rate, incidence of adverse events, and medication adherence. In the intention-to-treat analysis, the H. pylori eradication rates in the TA, TT, TAT, and TATB groups were 80.0% (95% confidence interval [CI]: 73.0-85.9), 61.9% (95% CI: 53.9-69.4), 93.1% (95% CI: 88.0-96.5), and 89.4% (95% CI: 83.5-93.7), respectively. Compared with the TATB regimen, the TAT regimen was non-inferior (95% CI, -3.9% to 11.5%; non-inferiority p < 0.001), whereas demonstrating non-inferiority in the TA and TT regimens failed. Adverse events were less frequent in the TA (10.6%), TT (17.5%), and TAT (20.0%) groups than in the TATB group (36.9%; all p < 0.001). Medication adherence was high across groups, with no significant between-group differences observed. High eradication efficacy was demonstrated for the TAT regimen; this regimen was non-inferior to the TATB regimen, and it was associated with fewer adverse events. These findings suggest that it may be an effective first-line treatment option for H. pylori infection. ClinicalTrials.gov identifier: NCT06977841.

PMID 42277990
阅读全文 →
PubMedJournal of global health2026-06-12

Outpatient management of children with chest indrawing pneumonia in primary healthcare settings in Punjab, Pakistan: a prospective cohort study.

Suhag Zamir Hussain ZH, Khuwaja Noorulain Altaf NA, Pal Ashlesha A, Naeem Muhammad M et al.

Pneumonia remains a leading cause of mortality among children under five years of age in Pakistan. The government of Pakistan revised the national Integrated Management of Childhood Illness (IMCI) protocol in 2019, recommending outpatient treatment of pneumonia, characterised by fast breathing and/or chest indrawing, with oral amoxicillin in children aged 2-59 months. We aimed to evaluate parents/caregivers-reported outcomes in children presenting with chest indrawing pneumonia at primary healthcare (PHC) facilities of Lahore, Punjab, Pakistan. We conducted a prospective observational cohort study from 3 January 2024 to 28 February 2025 at five PHC facilities in the peri-urban areas of Lahore. We enrolled children aged 2-59 months with chest indrawing pneumonia and followed them up on day 15 post-enrolment. The primary outcome was the case-fatality rate (CFR), and the secondary outcomes included antibiotic use, treatment adherence, and hospitalisation. Two physicians conducted verbal autopsies independently for children who died during the period of follow-up to determine the cause of death. We calculated CFRs with 95% confidence intervals (95% CI). We enrolled 360 children aged 2-59 months, of whom 356 (98.8%) completed the 15-day follow-up. The CFR for chest indrawing pneumonia was 0.6% (n/N = 2/356; 95% CI = 0.1-2.2). At follow-up, parents/caregivers reported that 336/356 (94.4%) children were cured, while 18/356 (5.0%) showed no improvement or had worsened health. Healthcare workers prescribed oral amoxicillin to 192/356 (53.9%) children, of whom 160/192 (83.3%) adhered to the specified duration of four or more days. On day 15 of follow-up, 26/356 (7.3%) parents/caregivers reported that they had switched to other antibiotics during treatment. Among these, 7/26 (26.9%) were hospitalised and received injectable antibiotics, 5/26 (19.2%) were managed as outpatients with injectable antibiotics, and 14/26 (53.8%) were treated with different oral antibiotics on an outpatient basis. The low CFR and high cure rate among children with chest indrawing pneumonia treated on an outpatient basis with oral antibiotics at the PHC settings in Lahore support the IMCI protocol. Management of chest indrawing pneumonia on an outpatient basis at the primary care level is feasible, with the potential to reduce unnecessary hospital referrals, reduce antimicrobial resistance, lower healthcare costs, and decrease mortality, particularly in resource-constrained settings. ISRCTN: ISRCTN12687253.

PMID 42281488
阅读全文 →
PubMedThe Journal of antimicrobial chemotherapy2026-06-12

Molecular surveillance of penicillinase-producing Neisseria gonorrhoeae to inform empiric treatment in remote settings: experience over 12 years.

Speers David J DJ, Minney-Smith Cara C, Simpson Hannah H, Rhodes Melissa M et al.

The remote regions of Western Australia (WA) have high gonorrhoea notification rates but low Neisseria gonorrhoeae penicillin resistance permitting the use of empiric combination oral amoxicillin, azithromycin and probenecid therapy. The predominance of molecular-based gonorrhoea diagnoses and consequent reduced phenotypic susceptibility data required PCR-based N. gonorrhoeae penicillin resistance surveillance to ensure the ongoing reliability of oral penicillin-based therapy for uncomplicated gonorrhoea in this setting. N. gonorrhoeae PCR-positive genital and non-genital specimens were systematically assessed across remote regions of WA for penicillinase production from 2012 to 2025 by detection of the N. gonorrhoeae TEM-1 plasmid using a specific real-time PCR. In 2012 <5% of N. gonorrhoeae positive samples in all remote regions were penicillinase-producing. By 2024, penicillinase detection rates had increased to >5% across three of the four remote regions prompting a review of the penicillin-based oral therapy in these regions. The continued recommendation of oral penicillin-based therapy for locally acquired uncomplicated gonorrhoea in a highly endemic setting must be evidence-based to ensure its reliability. Molecular penicillin resistance surveillance was successfully used for this purpose in the remote regions of WA where most gonorrhoea diagnoses are by molecular tests.

PMID 42283439
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lansoprazole + amoxicillin + clarithromycin